Friday, March 14, 2025 | 07:16 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

CLSA reiterates 'buy' on Star Health; sees 28% upside ahead

According to the report, Star has also rejected less claims till December FY24, though the company still had the highest rejection ratio

Star Health's IPO scrapes through as investment bankers prune OFS component
Premium

Shivam Tyagi New Delhi

Listen to This Article

Hong Kong based investment group CLSA has reiterated its ‘buy’ rating for standalone health insurance major Star Health, keeping the target price unchanged at Rs 715, an upside of 28 per cent. This is based on a few green signals shown by the company. 

Star is the second largest health insurer in India(retail and group basis).

The company’s stock was trading 0.9 per cent lower at Rs 553 on Tuesday’s intraday deals. The stock’s value grew by mere 7.7 per cent in FY24 while the Nifty50 index grew by 29 per cent during the same period. 

CSLA in its recent

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in